Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 712 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR ¿Puede protegerlo un “bronceado base” de las quemaduras solares y del... August 31, 2023 Cancer in My Community: Expanding Access to Genetic Testing in Mexico September 1, 2020 The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... September 20, 2021 Breast Cancer Patients With Anxiety or Depression More Prone to Opioid... August 27, 2019 Load more HOT NEWS Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... FDA Approves Idecabtagene Vicleucel for Multiple Myeloma Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story